

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 775 743 A2

EUROPEAN PATENT APPLICATION

(12)

(43) Date of publication:
28.05.1997 Bulletin 1997/22

(51) Int. Cl.⁶: C12N 5/16, A61K 39/255

(21) Application number: 96115575.1

(22) Date of filing: 27.09.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE
Designated Extension States:
AL LT LV SI

(72) Inventors:

- Coussens, Paul M.
DeWitt, Michigan 48820 (US)
- Abujoub, Amin
East Lansing, Michigan 48823 (US)

(30) Priority: 27.10.1995 US 549045

(71) Applicant: MICHIGAN STATE UNIVERSITY
East Lansing, Michigan 48824 (US)

(74) Representative: Grünecker, Kinkeldey,
Stockmair & Schwanhäusser
Anwaltssozietät
Maximilianstrasse 58
80538 München (DE)

(54) Sustainable chick cell line infected with Marek's disease virus

(57) A sustainable cell line of a Marek's disease herpesvirus (MDV) infected chicken cell line derived from chick embryo cells which are chicken helper factor (Chf) negative and which have been treated with N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and then converted

with the MDV which is able to infect avians *in vivo*. The cell line is useful for vaccine production and for determining the characteristics of the MDV under various conditions.




FIG. 1A

EP 0 775 743 A2

Description

BACKGROUND OF THE INVENTION(1) Summary of the Invention

The present invention relates to a sustainable chicken cell line infected with Marek's disease virus (MDV). In particular, the present invention relates to a cell line which can be used as a virus vaccine, as a system in which to produce altered MDV strains, and which can be used to determine the affect of various reagents or growth conditions on the cell line over time.

(2) Description of Related Art

Marek's disease (MD) is a highly contagious lymphoproliferative disease of chickens, characterized by lymphocytic infiltration in visceral organs, muscles, and peripheral nerves. The etiological agent of MD, an avian herpesvirus called Marek's disease virus (MDV), is highly infectious and cell associated (Calnek, B. W., and R. L. Witter, In "Diseases of Poultry: Marek's Disease" (B. W. Calnek, et al., Eds.), pp. 342-385, Iowa State University press, Ames, Iowa (1991)). MDV replicates in a productive restrictive manner in B-lymphocytes and cells growing in tissue culture. Production of fully enveloped virus is restricted to feather follicle epithelium of infected birds (Witter, R. L., et al., J. Natl. Cancer Inst. 49:1121-1130 (1972); Calnek, B. W., et al., Avian Dis. 14:219-233 (1970)). MDV rapidly establishes a latent infection in T-lymphocytes, ultimately leading to malignant transformation and neoplastic disease (Shek, W. R., et al., J. Natl. Cancer Inst. 70:485-491 (1983)). However, the precise relationship between latency and transformation in MDV infected T-lymphocytes is unknown. Akiyama, Y., et al. (Continuous cell culture from lymphoma of Marek's disease. Biken J. 16:177-179 (1973)) first succeeded in establishing a T-lymphoblastoid cell line from MD-infected chickens. Since then, more than 80 cell lines have been produced from MD lymphomas (Akiyama, Y., et al., Two cell lines from lymphomas of Marek's disease. Biken J. 17:105-116 (1974); Powell, P.C., et al., Nature 251:79-80 (1974); Calnek, B. W., et al., Int. J. Cancer 21:100-107 (1978); Payne, L. N., et al., Int. J. Cancer 28:757-766 (1981); Nazerian K., and R. L. Witter, J. Natl. Cancer Inst. 54:435-458 (1975)). Although suitable for some studies, these cell lines are many passages removed from the original event(s) leading to their transformation.

Evidence suggests that viral genomes in MD-lymphoblastoid cell lines are predominately integrated into cellular chromosomes, but episomal forms also exist (Delecluse, H.-J., et al., J. Virol. 67:82-92 (1993)). Analysis of viral transcription in transformed lymphoblastoid cell lines has revealed variable but limited transcriptional activity confined to approximately 20% of the viral genome (Maray, T., et al., Virus Genes 2:49-68 (1988)). MDV-specific transcripts in transformed lymphoblastoid cells are primarily derived from within long and short region terminal repeats (TRL and TRS respectively) and internal repeats (IRL and IRL respectively). Little transcriptional activity is detected within either the long unique (UL) or short unique (US) regions (Sugaya, K., et al., J. Virol. 64:5773-5782 (1990)). MDV can be rescued from some lymphoblastoid cell lines by cocultivation with primary or secondary chicken and duck embryo fibroblasts (CEF and DEF, respectively), which support the lytic cycle of MDV *in vitro* (Schat, K. A., et al., Int. J. Cancer 44:101-109 (1989)). In addition, some lymphoblastoid cell lines will induce MD upon injection into susceptible birds (Akiyama, Y., et al., Continuous cell culture from lymphoma of Marek's disease. Biken J. 16:177-179 (1973); Nazerian, K., et al., Avian Diseases 21:69-76 (1977)).

Since development of live virus Marek's disease vaccines in the late 1970's, losses to Marek's disease have been significantly reduced (Calnek and Witter, In "Diseases of Poultry: Marek's Disease" (B. W. Calnek, H. J. Barnes, C. W. Beard, W. M. Reid, and H. W. Yoder, Jr., Eds.), pp. 342-385, Iowa State University press, Ames IA (1991)). The most widely used Marek's disease vaccines are live Turkey herpesvirus (HVT or serotype 3 MDV) or a bivalent mixture of HVT and the apathogenic serotype 2 strain of MDV (MDV-2). The bivalent mixture of HVT and serotype 2 MDV synergistically affords greater protection against Marek's disease, especially in those situations where HVT is not fully effective (Witter, R. L., Protection by attenuated and polyvalent vaccines against highly virulent strain of Marek's disease virus. Avian Path. 11:49-62 (1982); Witter, R. L. and L. F. Lee, Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Path. 13:75-92 (1984); Witter, R. L., Principles of Vaccination. In "Marek's Disease: Scientific Basis and Methods of Control" (Payne, L. N., ed.) pp. 203-250. Mariner Nijhoff Pub., Boston, Massachusetts (1985)). Marek's disease vaccines are the most widely used vaccines in the poultry industry. Current Marek's disease vaccines are either suspensions of infected chicken embryo fibroblasts (CEF) or cell-free virus suspensions made from sonicated CEF infected with vaccine strains of MDV (MDV).

Two major difficulties in working with MDV are the strongly cell associated nature of the virus and the lack a sustainable cell culture system amenable to productive (lytic) infections. Primary CEF and DEF are permissive for MDV replication. However, these cultures have a finite life span (approximately 3 weeks), thus necessitating passage of infected primary cells onto an uninfected cell monolayer to propagate MDV and to obtain sufficient quantities of virus with which to work. Such conditions also preclude establishment of one-step growth experiments for effective temporal

The poultry industry has always recognized the need for continuous avian cell lines that could be used in producing Marek's disease vaccines and simplify development of recombinant MDV vectors for polyvalent vaccines. Although many avian cell lines have been developed (Nazarian, K., An updated list of avian cell lines and transplantable tumors. Avian Path. 12:527-544 (1987)), none of these can substitute for CEF cells in vaccine production. Previous cell lines failed because they were either derived from virally transformed cells or, if derived from chemically transformed cells, the cells produced tumors when inoculated into chickens. Since there are no sustainable cell lines suitable for propagating MDV, the MDV vaccine industry uses primary chicken embryo fibroblasts (CEF) for production of vaccine virus (Churchill, A. E., Production of Vaccines. In "Marek's Disease: Scientific Basis and Methods of Control" (Payne, L. N., ed.), pp. 251-265. Marinus Nijhoff Publishing, Boston, Massachusetts (1985)). Since primary CEFs have a finite life span, they must be prepared every week, increasing costs for producing MDV vaccines. For example, one major United States MDV vaccine producer utilizes 25,000 chick embryos every week. It is estimated that costs associated with purchase and preparation of chick embryos accounts for 40 to 45% of the total cost of MDV Vaccine production. A significant reduction in MDV vaccine production costs could be realized if a continuous cell line suitable for vaccine production were established. Requirements for such a cell line are: 1) The cell line can not be virally transformed, 2) Chemically transformed cell lines must be incapable of inducing tumors in vaccinated chickens, and 3) Virus titers produced by such a cell line must be equivalent (or nearly so) to titers obtained through infection of primary cells.

Development of a continuous cell line which would support growth with MDV experimentation and vaccine production.

It is therefore an object of the present invention to provide a sustainable cell line for MDV. Further still, it is an object of the present invention to provide a method for producing the sustainable MDV cell line. Further still, it is an object of the present invention to provide a method for infecting an avian to provide Marek's disease immunity. Further still, it is an object of the present invention to provide methods for producing the MDV cell line which is economical and a method for using the cell line which is effective. These and other objects will become increasingly apparent by reference to the following description and the drawings.

Figures 1A and 1B are photomicrographs showing uninfected and infected cells. Monolayer of uninfected CHCC-OU2 cells display a cobblestone appearance (Figure 1A), similar to that seen with primary CEF and DEF. At four weeks post-infection (as set forth in Example 1) numerous plaques consistent with MDV infection were observed on monolayers of M411n5/O12 cells (Figure 1B).

Figure 2 is an electrophoresis gel showing DNA from PCR amplification of MDV-specific sequences. PCR amplification was carried out on DNA isolated from Md11 infected CHCC-O2 cells (lanes 6-8). MDV-specific oligonucleotide primers (Table 1) were used to amplify particular MDV sequences, as set forth in Table 1. Negative control (lane 1), ICP4 gene promoter sequences (lane 2), 900 bp region of ICP4 coding sequence (lane 3), 1200 bp of *Bam*HI L fragment (lane 4), gC gene promoter sequences (lane 5), US3 gene promoter sequences (lane 6), and UL54 gene sequences (lane 7). Positions of selected bands were obtained from a 1kb ladder marker, which is not shown (Life Technologies, Inc., Gaithersburg, MD).

Figure 3 is an electrophoresis gel showing detection of viral DNA in infected CHCC-OU2 cells. DNA was extracted from cells, digested with *Bam*HI, electrophoresed on 0.8% agarose gels, transferred to Hybond-N-Nylon membranes, hybridized to non-radioactive probe under high stringency conditions, and autoradiographed. Cloned MDV DNA *Bam*HI fragments B, D, F, H, and I₂ were used as probes. Locations of each fragment were determined by comparison to a DNA size standard (lambda DNA digested with *Hind*III) and are indicated by an arrowhead to the left.

Figures 4A to 4C are Western blots for detection of specific MDV proteins. Cell lysates from uninfected CEF (CEF), Md1p15 infected CEF (Md1p15), uninfected CHCC-O2 cells (CHCC-O2), and Md1p15 infected O2 cells (MDV O2.2) were resolved on 12.5% SDS-polyacrylamide gels and transferred to nitrocellulose membranes, followed by immunodetection using specific antisera as described in Materials and Methods. In Figures 4A and 4B, positions of molecular size markers (in KiloDaltons), are indicated. Figure 4A shows detection of MDV-specific protein pp38 using a monoclonal antibody (generously provided by Dr. Lucy Lee, USDA-ADOL, East Lansing, MI). Figure 4B shows detection of MDV-specific protein pp14 using polyclonal antisera generated against pp14 fusion proteins (Hong, Y., and P. M. Coussens, J. Virol. 68:3593-3603 (1994)). Figure 4C protein loading in each lane was verified by detection of α -actin using a commercial antibody (Santa Cruz Biotechnology, Santa Cruz, CA).

Figure 5 is an electrophoresis gel showing DNA from PCR amplification of 850 bp pp38 gene segment. PCR amplification was carried out on DNA isolated from kidneys of birds injected with CHCC-OU2 (lanes 2 and 3). MDV OU2.2

(lanes 4-6), and Md11p16 infected CEF (lanes 7 and 8). Negative control (lane 1) included all reaction components except template DNA. Additional controls included DNA isolated from uninfected CEF (lane 9), and DNA isolated from Md11p16 infected CEF as positive control (lane 10). In each case (except negative control), 300 ng DNA was used as template for PCR amplification using pp38 specific primers (Table 1). PCR products were analyzed on 12% agarose gels containing 10 µg/ml ethidium bromide. Fragment sizes were determined relative to DNA size standards, which are not shown (1 Kb Ladder, Life Technologies, Gaithersburg MD).

DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention relates to a sustainable Marek's disease virus (MDV) infected chicken cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N¹-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*.

Further, the present invention relates to a method for infecting an avian with Marek's disease virus (MDV) which comprises: providing a vaccine produced by a sustainable Marek's disease virus (MDV) infected chicken cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N¹-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*; and inoculating the avian with the vaccine.

Finally, the present invention relates to an avian vaccine in dosage unit form containing a sustainable Marek's disease virus (MDV) infected fibroblast cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N¹-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*.

The new MDV infected cell lines are "sustainable" which means that it can be maintained in culture for long periods of time (at least nineteen months) without requiring passage. This is a great improvement over multiple passaging in CEC cells as in the prior art.

The virus free cell line CHCC-OU2 is maintained on deposit at Michigan State University and by the USDA and is a known cell line and is freely available upon request. Similarly MDV infected CHCC-OU2 cells deposited under the Budapest Treaty on September 28, 1995, as ATCC CRL-11985 (MDVOU2.2) and is available upon request by name and number.

The MDV infected cell line can be used to produce a vaccine so long as the virus is non-oncogenic. The MDV infected cell line can also be used to test various agents or conditions which suppress or enhance cell response, such as repressing tumor production.

The preferred MDV is a virus selected from Serotypes 1, 2 or 3. Serotype 3 MDV is also referred to as turkey herpesvirus (HVT). The MDV can be a recombinant or deletion mutant which is used as a vaccine or for other uses.

The present invention particularly relates to continuous chick fibroblast cell lines (MDV OU 2.1 and MDV OU 2.2), stably infected with MDV strain Md11 at passage level 15. MDV OU2.1 and MDV OU2.2 cells grow continuously in culture and, once confluent, display plaques characteristic of MDV infection. MDV OU2.1 and MDV OU2.2 cells can be used to transfer infection to CEF, and produce classic symptoms of MD in susceptible birds. MDV OU2.2 cells have remained viable and continue to produce MDV after cryogenic storage and continuous culture for over 19 months.

As shown in the following Example 1, Southern blot and PCR analyses demonstrate that these cell lines harbor MDV DNA. Western blot analyses indicate that MDV OU2.2 cells express at least a limited set of viral proteins, pp 38 and pp14, similar to that seen in MDV lymphoblastoid cells. Presence of distinct plaques in confluent MDV OU2.2 cell monolayers is consistent with cytolytic semi-productive infection, similar to that observed in primary CEF. MDV OU2.2 cells are capable of transferring MDV infection to primary CEF cultures and inducing clinical signs of Marek's disease (MD) in susceptible birds. MDV OU2.2 cells have maintained a MDV positive phenotype for over 19 months of active culture.

EXAMPLE 1

MATERIALS AND METHODS

Cells and Virus

Preparation, propagation, and infection of CEF cells with MDV were performed as described previously (Glaubiger, C., et al., J. Virol. 45:1228-1234 (1983); Coussens, P. M., and L. F. Velicer, J. Virol. 62:2373-2379 (1988)). The very virulent MDV strain Md11 was used in this study at cell culture passage level 15 (Md11p15). CHCC-OU2 cells (Ogura, H., et al., Acta Med. Okayama 41:141-143 (1987)) were obtained from Dr. Donald Salter, Avian Disease and Oncology Laboratories (ADOL), U.S. department of Agriculture (USDA), East Lansing, Michigan, and were cultured in Leibovitz L15-McCoy 5A (LM) (Gibco, Inc., Grand Island, NY) media (carbon, nitrogen source) supplemented with 10% fetal bovine

serum (FBS) and 2% tryptose phosphate broth (TPB) at 37°C in a humidified atmosphere containing 5% CO₂.

CHCC-OU2 cells were infected with MDV strain Md11p15 by combining 5.0×10^7 CHCC-OU2 cells with 2.0×10^7 Md11p15 infected CEF prior to plating on 150 mm culture dishes in LM medium supplemented with 4% calf serum (CS). Co-cultivation of CHCC-OU2 cells with Md11 infected CEF cells was continued for four passages. Cells from each of these passages have been preserved at -135°C in freezing media (LM media (Life Technologies, Gaithersburg, MD, McCoy's 5A medium) supplemented with 20% CS and 10% dimethyl sulfoxide (DMSO)). At four passages post-infection, numerous plaques (approximately 100 plaques per 150mm culture dish), characteristic of MDV infections in CEF cells, were observed. Two of these plaques were isolated using sterile cloning cylinders. Cylinders were placed on top of individual plaques, cells were trypsinized and aspirated from the cloning cylinders. Aspirated cells were transferred to 35 mm culture dishes containing LM media supplemented with 4% CS for expansion. During expansion, cells were not allowed to become confluent and media was changed every 48 to 72 hours. Expanded clones were designated MDV OU2.1 and MDV OU2.2.

Preparation of cellular DNA, Southern blot analysis, and PCR.

Total cellular DNA was extracted from uninfected and MDV-infected CHCC-OU2 cells by standard methods (Sambrook, J., et al., Molecular cloning a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989)). Restriction enzymes (Boehringer Mannheim Biochemicals, Indianapolis, IN) were used according to the manufacturers recommendation. DNA was digested, electrophoresed through 0.8% agarose gels and transferred to Hybond-N nylon membranes (Amersham Corp., Arlington Heights, IL) by Southern blotting (Southern, E. M., Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503 (1975)). Probes were non-radioactively labeled (Digoxigenin-11-dUTP) using a random primer labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN).

Total cellular DNA was also used as template for PCR amplification of MDV specific sequences. Primers used and expected fragment sizes are indicated in Table 1.

TABLE 1

Sequence of MDV-specific oligonucleotide primers used in PCR amplification.		
Primer Sequences*	Locus	Expected Size (kbp)
GTAGTGAATCTATACCTGGG	gC gene promoter	0.3
GTGTCTAGAGAGGGAAGATATGTAGAGGGTTAC		
ATGGAATTGGAAGCAGACAC	pp38 gene	0.85
CTCCAGATTCACCTCCCCAGA		
TGCTAATTGTGGTCC	ICP4 gene	0.9
GGTGCTTCCATCTCGGC		
GATCTAGACGTTTCTGCCTCCGGAGTC	US3 gene promoter	0.6
GCAAGCTTCAACATCTTCAAATGCGGCAC		
GTCTAGACGCGATAGCGAGTTGTTGGACC	ICP4 gene promoter	1.1
GGAAGCTTTATTAAAGGAGATTCTACCC		
GTGAAAGAGTGAACGGGAAG	BamHI L fragment	1.2
CGTCAAAGCGATAATAGGC		
CCGGGGATCCCGAAATGTCGTTAGAACATC	ULS4 gene	1.1
CGGGGTCGACTAAGGCAAATAGGCACGC		

*Primer sequences are written as 5' to 3', left to right. In each case, the upper primer represents the upstream sequence while the lower primer represents the downstream sequence. They are set forth in Appendices 1 to 14.

Briefly, 300 ng of total cellular DNA was combined with 25 mM each dNTP (dATP, dCTP, dGTP, and dTTP), 20 mM of each appropriate primer pair, 10 µl of 10X PCR reaction buffer (Perkin Elmer Cetus, Norwalk, Connecticut), and 2.5 Units Tag polymerase (Perkin Elmer Cetus, Norwalk, Connecticut). PCR reactions were performed using a GeneAmp 9600 thermal cycler (Perkin Elmer Cetus, Norwalk, Connecticut) as follows: 35 cycles of 95°C for 20 sec, 56°C for 20 sec, and 72°C for 30 sec. Two controls, one without DNA and one with uninfected CHCC-OU2 DNA were included in each experiment. High molecular weight DNA isolated from uninfected CEF and CEF infected with Md11p16 were used as controls for specific amplification. PCR products were purified using the Wizard PCR prep kit (Promega Inc., Madison, Wisconsin) as recommended by the manufacturer) and analyzed on 12% agarose gels.

Western immunoblot analysis.

Cultured cells were collected and sonicated using a Sonifier cell disrupter model 350 (Branson Ultrasonic Corporation, Danbury, Connecticut). Proteins (20 µg) from each cell type were separated on 12.5% polyacrylamide/1% SDS gels. Separated proteins were electrophoretically transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat milk and probed with antibodies to MDV proteins: pp14 (Hong, Y., and P. M. Coussens, J. Virol. 68:3593-3603 (1994)), and pp38 (Cui, Z., et al., J. Virol. 65:6509-6515 (1991)). Immune complexes were detected by incubation with a donkey anti-mouse or anti-rabbit immunoglobulin conjugated with horseradish peroxidase. Detection was performed using an ECL Western blot kit (Amersham Corp., Arlington Heights, IL) according to the manufacturer's recommendations and exposed to X-ray film. Protein sizes were estimated by comparison to prestained protein molecular weight standards (Bio-Rad, Richmond, CA) electrophoresed on the same gel.

Inoculation of chickens with cells and virus.

In vivo experiments were performed using specific pathogen free chickens (line 1515X 71), obtained from the Avian Disease and Oncology Laboratory, U.S. Department of Agriculture, East Lansing, Michigan. Three groups of chicks

each at one day of age, were inoculated intraperitoneally with (1) uninfected CHCC-OU2 cells, (2) 1000 plaque forming units (PFU) of Md11p16 in CEF, and (3) 1000 PFU of MDV infected OU2 cells (MDV OU2.2). The first and second groups served as controls (negative and positive, respectively).

Birds were euthanized and necropsied upon signs of morbidity. Blood was collected for isolation of peripheral blood lymphocytes and co-cultivation with CEF as an assay for viable virus. Kidney, spleen, and liver were harvested for DNA isolation and histological evaluation. Total tissue-specific DNA was isolated and used as template for PCR amplification of MDV sequences employing primer sets detailed in Table 1.

RESULTS

Infection of CHCC-OU2 cells with Md11p15:

Although CHCC-OU2 cells are chemically immortalized, they are not malignantly transformed, maintain contact inhibition, and exhibit many morphological features of normal chick fibroblasts. CHCC-OU2 cells were co-cultivated with Md11p15 infected CEF cells. Cytopathic effect (CPE), characterized by formation of spherical cells loosely attached to the substratum, was first observed on co-cultivation cell monolayers at two weeks post-infection. The majority of these regions were characterized as "microplaques", consisting of relatively small clusters of rounded cells. CPE was slow in developing and expanding. Fully developed plaques consisting of syncytia and extended regions of rounded, loosely attached, cells were not visible until four weeks post-infection (Figure 1). The appearance of visible plaques 14 days after infection and the dependence of plaque formation on the cells reaching confluency and contact inhibition was not expected. By comparison, a typical CEF monolayer infected with MDV strain Md11 will develop readily visible plaques in 5-7 days post-infection with complete destruction of the monolayer within 10-14 days. Plaque formation in CEF is independent of the confluency of the cell monolayer. After four weeks of co-cultivation, cells were cryogenically preserved at -135°C for two weeks. Cell cultures were re-established from frozen cells by combining infected (Md11p15/OU2) and uninfected CHCC-OU2 cells. Plaques consistent with MDV infection were not observed until cells reached confluency, approximately 14 days post-plating.

Detection of MDV DNA in infected CHCC-OU2 cells.

Polymerase chain reaction (PCR) was used as an initial assay for presence of MDV DNA in infected CHCC-OU2 cells. Three hundred ng of total DNA from Md11p15/OU2 and uninfected CHCC-OU2 cells was used as template for PCR amplification with several primer pairs corresponding to various MDV genes, as described in Materials and Methods. Bands of appropriate sizes (Table 1) were obtained in reactions with Md11p15/OU2 DNA but not from uninfected OU2 DNA templates (Figure 2). Reactions containing DNA isolated from uninfected CEF and Md11 infected CEF were used as negative and positive controls, respectively (data not shown).

Results of PCR analyses indicated that MDV DNA was present in infected CHCC-OU2 cultures. Although unlikely, given our extended culture conditions, PCR analysis could have detected MDV DNA from residual Md11p15 infected CEF cells. In addition, PCR analyses do not provide critical information on integrity of MDV DNA in Md11p15/OU2 cells. To address these concerns, MDV DNA in infected CHCC-OU2 cells was analyzed by Southern blot hybridization using a cocktail of MDV BamHI fragments (B, F, H, and I₂) as a probe. Total genomic DNA isolated from Md11p16 infected CEF and Md11p15/OU2 cells contained MDV specific fragments corresponding to BamHI fragments B, F, H and I₂. As expected, similar fragments were not detected in DNA isolated from uninfected CEF or CHCC-OU2 cells (Figure 3).

Establishment of Infected cell lines

Although culture conditions and freeze-thaw cycles should have eliminated most of the original CEF cells used for establishing infection, it was possible that residual CEF cells were contributing to MDV specific DNA detected in our Md11p15/OU2 cultures. To address this concern, isolation and expansion of individual plaques from infected CHCC-OU2 cultures was initiated. Two Md11p15/OU2 cell lines (MDV OU2.1 and MDV OU2.2) were established by plaque isolation and expansion as described in Materials and Methods. Despite arising from distinct plaques, both cell lines exhibited initial growth characteristics indistinguishable from uninfected CHCC-OU2 cells. Plaques characteristic of MDV infection were only observed in MDV OU2.1 and MDV OU2.2 cell cultures after confluency had been reached at 10 to 14 days post-plating.

To confirm infectious virus could be rescued from MDV OU2.1 and MDV OU2.2 cultures, cells from each isolate were used as inoculum to infect CEF cells by combining 1×10^6 MDV OU2.1 or MDV OU2.2 with 5×10^7 secondary CEF. Plaques consistent with MDV infection of CEF cells were visible within 5 days post co-cultivation. In contrast, no plaques were evident in control plates containing 1×10^6 uninfected CHCC-OU2 cells and 5×10^7 CEF cells.

Detection of viral proteins expressed in MDV OU2.2 cells.

To verify that MDV OU2.2 cells indeed supported replication and growth of MDV, detection of MDV proteins was initiated. Monoclonal antibodies to pp38 (generous gift from Dr. Lucy Lee, USDA-ADOL, East Lansing, Michigan), detected a band of approximately 38 kDa in extracts from confluent MDV OU2.2 cells and Md11p16 infected CEF, but not in extracts from uninfected CHCC-OU2 or CEF cells (Figure 4A). Polyclonal antisera to pp14, an MDV-specific immediate-early phosphoprotein (Hong, Y., et al., J. Virol. 68:3593-3603 (1994)) also reacted with an appropriately sized polypeptide in extracts from confluent MDV OU2.2 cells and Md11p16 infected CEF cells but not in uninfected cell extracts (Figure 4B). A polyclonal antiserum to α -actin was used to ensure similar amounts of protein were analyzed in each lane (Figure 4C). Taken together, results of PCR amplification, Southern hybridization, and Western blot analysis indicated that MDV OU2.2 cells represent a continuous anchorage dependent cell line which harbors MDV and is permissive for semi-productive infection.

MDV OU2.2 cells induce MD in susceptible chickens

Marek's disease can be experimentally induced by injection of MDV infected cells into susceptible birds. MDV lymphoblastoid cell lines such as MSB-1 are also able to induce MD in susceptible birds following intraperitoneal injection. Also, most commercially available MDV vaccines are comprised of CEF cells infected with vaccine strains of MDV. The infectious but apathogenic vaccine strains of MDV are transferred to birds after inoculation where it replicates, inducing humoral and cell mediated responses. To determine if MDV OU2.2 cells could transfer MDV to birds in a similar manner, 151₅ X 7₁ chickens were inoculated with uninfected CHCC-OU2 cells, MDV OU2.2 cells, or Md11p16 infected CEF cells at one day of age. Chickens injected with either Md11p16 infected CEF or with MDV OU2.2 cells developed classical signs of MD (reduced growth and paralysis of neck, wings, and legs) as early as 10 days post-infection. In contrast, negative control chickens injected with uninfected CHCC-OU2 cells showed no clinical signs of MD, even at 12 weeks of age.

To confirm presence of MDV in infected birds, peripheral blood lymphocytes (PBLs) were isolated from blood collected at various times post-inoculation and seeded onto secondary CEF. Plaques consistent with MDV infection were observed on CEF monolayers at 4 days post-culture on plates seeded with PBLs isolated from birds injected with Md11p16 infected CEF or MDV OU2.2 cells. No plaques were observed on plates of CEF cells mixed with PBLs obtained from control birds injected with uninfected CHCC-OU2 cells.

To further confirm replication of MDV in infected birds, total cellular DNA isolated from infected bird kidneys was used as template for PCR amplification using primers specific for the MDV pp38 gene. Consistent with the presence of MDV DNA an 850 bp fragment was amplified using DNA isolated from kidneys of birds injected with Md11p16 infected CEF or MDV OU2.2 cells. In contrast, similar bands were not detected when DNA from birds injected with CHCC-OU2 cells was used as template (Figure 5).

Histological evaluation revealed lymphocyte infiltration and early, active lymphomas in various tissues from birds injected with CEF/Md11p16 and MDV OU2.2, whereas CHCC-OU2 inoculated birds showed no signs of MD at the microscopic level. Taken together, these results clearly demonstrate that MDV OU2.2 cells contain MDV and that the virus may be transferred to birds via intraperitoneal injection.

One of the major difficulties in working with MDV is lack of a sustainable cell culture system for virus growth and selection. Although primary CEF and DEF are permissive for MDV replication, primary cultures are characterized by slow growth and limited life span. These factors necessitate continual passage of infected cells onto uninfected cells in order to obtain sufficient quantities of virus with which to work. In addition, CEF and DEF must be prepared on a regular basis from 10 or 11 day old chick embryos, adding significantly to the expense and difficulty of culturing MDV.

The CHCC-OU2 cell line is an immortalized fibroblastic cell line derived from chick embryo cells (Ogura, H., et al., Acta Med. Okayama 41:141-143 (1987)). CHCC-OU2 are not oncogenic, based on the fact that CHCC-OU2 cells failed to produce tumors when injected into syngeneic chickens (Ogura, H., et al., Acta Med. Okayama 41:141-143 (1987)). In addition CHCC-OU2 are virus free and susceptible to avian retrovirus infection (avian sarcoma viruses of subgroups A, B, and C). Newcastle disease virus also replicates well in CHCC-OU2 cell cultures (Ogura, H., et al., Acta Med. Okayama 41:141-143 (1987)).

As can be seen from Example 1, the CHCC-OU2 cells are suitable as a sustainable cell culture system for replication and study of MDV. The initial phase of CHCC-OU2 infection with MDV was slow and characterized by a low number of visible plaques. Fully developed plaques were first observed at four weeks post-infection. At this time, plaques were clearly visible and quite abundant (approximately 100 plaques/150 mm tissue culture plate). In subsequent passages, plaques were visible every 10-14 days in culture.

Southern blot and PCR analyses confirmed that semi-clonal cell lines, MDV OU2.1 and MDV OU2.2, indeed harbor MDV DNA. Fragments detected by Southern blot hybridization were similar in size to those detected in Md11p15 infected CEF, indicating that no gross structural rearrangements had occurred. In addition, fragments detected in MDV OU2.2 cell DNA represent diverse regions of the MDV genome, including the unique long (BamHI B and F), terminal

repeat long (BamHI D), and internal repeat long (BamHI H and I₂) segments. Intensity of these fragments suggests that MDV OU2.2 cells allow MDV DNA replication, as it is highly unlikely the observed amount of DNA would arise from residual CEF cells used to establish initial infections.

Western blot analyses demonstrated that MDV OU2.2 cells express at least a limited set of viral proteins, pp38 and pp14. Despite numerous attempts, we were unable to detect MDV glycoproteins gC, gB, gE, and gI by western blot analyses. Each of the particular antisera employed was able to detect the respective protein in Md11p15 infected CEF cell extracts. Thus, results of western blot analyses are consistent with MDV existing in MDV OU2.2 cells as a latent infection, similar to that seen in MDV lymphoblastoid cells. However, presence of distinct plaques in MDV OU2.2 cell monolayers is not consistent with latent infection as this would imply cytolitic activity related to MDV infection. However, presence of distinct plaques in confluent MDV OU2.2 cell monolayers imply cytolitic activity related to MDV infection is dependent on contact inhibition.

The *in vivo* and *in vitro* experiments demonstrated that in all respects MDV propagated in OU2 cells was structurally and biologically indistinguishable from MDV propagated in CEF. Preliminary experiments with vaccine viruses, SB1 and FC126, indicate that these viruses replicate in the same manner as Md11p15 in OU2 cells. These experiments also indicated that these infected OU2 cells, like OU2 cells infected with Md11p15, are infectious and can transfer virus to CEF. The preliminary data with the vaccine strains of MDV and the *in vivo* data of Md11p15 suggest that vaccines comprised of OU2 cells infected with vaccine strains of MDV will be just as effective as the current vaccines comprised of CEF infected with vaccine strains of MDV.

EXAMPLE 2

CHCC-OU2 cells were infected with MDV serotype-2 vaccine strain SB1 by infecting CHCC-OU2 monolayers comprised of 4×10^6 cells on 100 mm culture dishes with 3.1×10^6 SB1 infected CEF. Co-cultivation was continued for four passages. At every passage, progressively more plaques, characteristic of MDV infections, were observed.

EXAMPLE 3

CHCC-OU2 cells were infected with MDV serotype-3 (HVT) vaccine strain Fc126 by infecting CHCC-OU2 monolayers comprised of 4×10^6 cells on 100 mm culture dishes with 3.3×10^6 HVT infected CEF. Co-cultivation was continued for four passages. At passage three, plaques, characteristic of MDV infections, were observed.

In vivo experiments clearly demonstrate that MDV OU2.2 cells are capable of transferring MDV infection to CEF monolayer cultures and inducing clinical signs of MD in susceptible birds. Birds injected with either MDV OU2.2 or Md11p16 infected CEF, developed clinical signs of MD, characterized by a marked decrease in growth rate and paralysis of legs, wings, and neck. PCR analysis of tissues, including kidney and spleen, demonstrated that MDV was present in remote tissues of birds injected with MDV OU2.2 cells. In addition, PBLs isolated from birds injected with MDV OU2.2 cells were able to transfer infection to CEF monolayers. In contrast, no evidence of tumor formation or viremia was observed in birds inoculated with uninfected CHCC-OU2 cells.

The *in vivo* experiments clearly demonstrate that MDV infected CHCC-OU2 cells can be used to establish infections in susceptible birds, a quality of considerable importance for MDV vaccine development and production of MDV mutants by positive selection.

The foregoing description is only illustrative of the present invention and the present invention is limited only by the hereinafter appended claims.

APPENDIX I

(1) GENERAL INFORMATION:

- (i) Applicant: Paul M. Coussens and Amin Abujoub
 - (ii) Title of Invention: SUSTAINABLE CHICK CELL LINE INFECTED WITH MAREK'S DISEASE VIRUS
 - (iii) Number of Sequences: 14
 - (iv) Correspondence Address:
 - (A) Addressee: Ian C. McLeod
 - (B) Street: 2190 Commons Parkway
 - (C) City: Okemos
 - (D) State: Michigan
 - (E) Country: USA
 - (F) Zip: 48864
 - (v) Computer Readable Form:
 - (A) Medium Type: Diskette 5.25 inch, 360 kb storage
 - (B) Computer: Acer
 - (C) Operating System: MS-DOS (version 3.3)
 - (D) Software: Wordperfect 5.1
 - (vi) Current Application Data:
 - (A) Application Number:
 - (B) Filing Date:
 - (C) Classification:
 - (vii) Prior Application Data:
 - (A) Application Number:
 - (B) Filing Date:
 - (viii) Attorney/Agent Information:
 - (A) Name: Ian C. McLeod
 - (B) Registration No.: 20,931
 - (C) Reference/Docket Number: MSU 4.1-270
 - (ix) Telecommunication Information:
 - (A) Telephone: (517) 347-4100
 - (B) Telefax: (517) 347-4103
- (2) Information for SEQ ID NO: 1

- (i) Sequence Characteristics:
 (A) Length: 21 Base Pairs
 (B) Type: Nucleic Acid
 (C) Strandedness: Single
 (D) Topology: Linear
- (ii) Molecule Type:
 (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
 (A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
 (A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

GTACTGAAAT CTATACCTGG G

21

- (3) Information for SEQ ID NO: 2
- (i) Sequence Characteristics:
 (A) Length: 33 Base Pairs
 (B) Type: Nucleic Acid
 (C) Strandedness: Single
 (D) Topology: Linear
- (ii) Molecule Type:
 (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
 (A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
 (A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GTGTCTAGAG AGGGAAGATA TGTAGAGGGT TAC

33

- (4) Information for SEQ ID NO: 3
- (i) Sequence Characteristics:
 (A) Length: 21 Base Pairs

- (B) Type: Nucleic Acid
(C) Strandedness: Single
(D) Topology: Linear
(ii) Molecule Type:
(A) Description: Synthetic DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE:
(A) Organism: Marek's Disease Virus
(vii) IMMEDIATE SOURCE:
(A) Library:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATGGAATTCG AAGCAGAACA C

21

(5) Information for SEQ ID NO: 4

- (i) Sequence Characteristics:
(A) Length: 22 Base Pairs
(B) Type: Nucleic Acid
(C) Strandedness: Single
(D) Topology: Linear
(ii) Molecule Type:
(A) Description: Synthetic DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE:
(A) Organism: Marek's Disease Virus
(vii) IMMEDIATE SOURCE:
(A) Library:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CTCCAGATTC CACCTCCCCA GA

22

(6) Information for SEQ ID NO: 5

- (i) Sequence Characteristics:
(A) Length: 16 Base Pairs
(B) Type: Nucleic Acid
(C) Strandedness: Single
(D) Topology: Linear

- (ii) Molecule Type:
 - (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
 - (A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
 - (A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGCTAATTGT GGCTCC

16

(7) Information for SEQ ID NO: 6

- (i) Sequence Characteristics:
 - (A) Length: 17 Base Pairs
 - (B) Type: Nucleic Acid
 - (C) Strandedness: Single
 - (D) Topology: Linear
- (ii) Molecule Type:
 - (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
 - (A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
 - (A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGTGCTTCCA TCTCGGC

17

(8) Information for SEQ ID NO: 7

- (i) Sequence Characteristics:
 - (A) Length: 27 Base Pairs
 - (B) Type: Nucleic Acid
 - (C) Strandedness: Single
 - (D) Topology: Linear
- (ii) Molecule Type:
 - (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:

- (A) Organism: Marek's Disease Virus
 (vii) IMMEDIATE SOURCE:
 (A) Library:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
 GATCTAGACG TTTCTGCCTC CGGAGTC 27

(9) Information for SEQ ID NO: 8

- (i) Sequence Characteristics:
 (A) Length: 30 Base Pairs
 (B) Type: Nucleic Acid
 (C) Strandedness: Single
 (D) Topology: Linear
 (ii) Molecule Type:
 (A) Description: Synthetic DNA
 (iii) HYPOTHETICAL: No
 (iv) ANTI-SENSE: No
 (vi) ORIGINAL SOURCE:
 (A) Organism: Marek's Disease Virus
 (vii) IMMEDIATE SOURCE:
 (A) Library:
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GCAAGCTTCA ACATCTTCAA ATAGCCGCAC 30

(10) Information for SEQ ID NO: 9

- (i) Sequence Characteristics:
 (A) Length: 29 Base Pairs
 (B) Type: Nucleic Acid
 (C) Strandedness: Single
 (D) Topology: Linear
 (ii) Molecule Type:
 (A) Description: Synthetic DNA
 (iii) HYPOTHETICAL: No
 (iv) ANTI-SENSE: No
 (vi) ORIGINAL SOURCE:
 (A) Organism: Marek's Disease Virus
 (vii) IMMEDIATE SOURCE:
 (A) Library:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTCTAGACGC GATAGCGAGT TGTGGACC

29

(11) Information for SEQ ID NO: 10

(i) Sequence Characteristics:

(A) Length: 28 Base Pairs

(B) Type: Nucleic Acid

(C) Strandedness: Single

(D) Topology: Linear

(ii) Molecule Type:

(A) Description: Synthetic DNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

(A) Organism: Marek's Disease Virus

(vii) IMMEDIATE SOURCE:

(A) Library:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGAAGCTTTA TTAAGGGAGA TTCTACCC

28

(12) Information for SEQ ID NO: 11

(i) Sequence Characteristics:

(A) Length: 20 Base Pairs

(B) Type: Nucleic Acid

(C) Strandedness: Single

(D) Topology: Linear

(ii) Molecule Type:

(A) Description: Synthetic DNA

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(vi) ORIGINAL SOURCE:

(A) Organism: Marek's Disease Virus

(vii) IMMEDIATE SOURCE:

(A) Library:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GTGAAAGAGT GAACGGGAAG

20

(13) Information for SEQ ID NO: 12

- (i) Sequence Characteristics:
(A) Length: 19 Base Pairs
(B) Type: Nucleic Acid
(C) Strandedness: Single
(D) Topology: Linear
- (ii) Molecule Type:
(A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
(A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
(A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CGTCAAAGCG ATAATAGGC

19

(14) Information for SEQ ID NO: 13

- (i) Sequence Characteristics:
(A) Length: 30 Base Pairs
(B) Type: Nucleic Acid
(C) Strandedness: Single
(D) Topology: Linear
- (ii) Molecule Type:
(A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
(A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
(A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCGGGGATCC CGAATGTCG TTGAACATC

30

(15) Information for SEQ ID NO: 14

- (i) Sequence Characteristics:
(A) Length: 28 Base Pairs
(B) Type: Nucleic Acid
(C) Strandedness: Single

- (D) Topology: Linear
- (ii) Molecule Type:
- (A) Description: Synthetic DNA
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (vi) ORIGINAL SOURCE:
- (A) Organism: Marek's Disease Virus
- (vii) IMMEDIATE SOURCE:
- (A) Library:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CGGGGTCGAC TAAGGCAAT AGGCACGC

28

Claims

1. A sustainable Marek's disease virus (MDV) infected chicken cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*.
2. The cell line of Claim 1 wherein the MDV is a virus used for the preparation of a virus vaccine to produce immunity.
3. The cell line of Claim 1 wherein the MDV is a virus selected from the group consisting of serotype 1, serotype 2, or serotype 3 MDV wherein serotype 3 is a turkey herpesvirus (HVT).
4. The cell line of Claim 1 wherein the MDV is a genetically engineered MDV comprising one or more foreign genes inserted into a site in MDV.
5. The cell line of Claim 1 wherein the MDV comprises one or more foreign genes which have been deleted.
6. An immortalized Marek's disease herpesvirus cell line deposited as ATCC CRL 11985 containing Marek's disease strain Md11.
7. The cell line of Claim 1 wherein the CEC fibroblasts are CHCC-OU2.
8. A method for producing a sustainable Marek's disease virus (MDV) infected chicken cell line which comprises:
 - (a) combining chick embryo cells (CEC) which are chicken helper factor free and virus-free and have been treated with N-methyl N-nitro-N-nitrosoguanidine (MNNG) with MDV virus in a culture medium so that the CEC are infected with MDV; and
 - (b) purifying the MDV infected CEC from uninfected CEC; and
 - (c) propagating the MDV infected CEC to produce the cell line.
9. The method of Claim 8 wherein MDV virus is selected from the group consisting of cell-associated MDV virus derived from primary embryo fibroblasts, cell-free MDV, or MDV DNA transfected into CEC.
10. The method of Claim 8 wherein the MDV is a virus used for the preparation of a virus vaccine to produce immunity.
11. The method of Claim 8 wherein the MDV is a virus selected from the group consisting of serotype 1, serotype 2, or serotype 3 MDV wherein serotype 3 is a turkey herpesvirus (HVT).

12. The method of Claim 8 wherein the MDV is a genetically engineered MDV comprising one or more foreign genes inserted into a site in MDV.
13. The method of Claim 8 wherein the MDV comprises one or more foreign genes which have been deleted.
14. The method of Claim 8 wherein an immortalized Marek's disease herpesvirus cell line deposited as ATCC CRL-11985 containing Marek's disease strain Md11.
15. The method of Claim 8 wherein the CEC fibroblasts is CHCC-OU2.
16. A method for infecting an avian with Marek's disease virus (MDV) which comprises:
 - (a) providing a vaccine produced by a sustainable Marek's disease virus (MDV) infected chicken cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*; and
 - (b) inoculating the avian with the vaccine.
17. The method of Claim 16 wherein the inoculation is by injection.
18. The method of Claim 16 wherein the MDV is a virus used for the preparation of a virus vaccine to produce immunity.
19. The method of Claim 16 wherein the MDV is a virus selected from the group consisting of serotype 1, serotype 2, or serotype 3 MDV wherein serotype 3 is a turkey herpesvirus (HVT).
20. The method of Claim 12 wherein the MDV is a genetically engineered MDV comprising one or more foreign genes inserted into a site in MDV.
21. The method of Claim 12 wherein the MDV comprises one or more foreign genes which have been deleted.
22. The method of Claim 16 wherein an immortalized Marek's disease herpesvirus cell line deposited as ATCC CRL-11985 containing Marek's disease strain Md11.
23. The method of Claim 6 wherein the CEC fibroblasts is CHCC-OU2.
24. The method of Claim 12 wherein the vaccine contains the sustainable MDV cell line.
25. An avian vaccine in dosage unit form containing a sustainable Marek's disease virus (MDV) infected fibroblast cell line derived from chick embryo cells (CEC) which are chicken helper factor (Chf) negative and virus-free and which have been treated with N-methyl-N¹-nitro-N-nitrosoguanidine (MNNG) and then are infected with MDV which is able to infect avians *in vivo*.
26. The vaccine of Claim 25 wherein the MDV is a virus used for the preparation of a virus vaccine to produce immunity.
27. The method of Claim 25 wherein the MDV is a virus selected from the group consisting of serotype 1, serotype 2, or serotype 3 MDV wherein serotype 3 is a turkey herpesvirus (HVT).
28. The method of Claim 19 wherein the MDV is a genetically engineered MDV comprising one or more foreign genes inserted into a site in MDV.
29. The method of Claim 19 wherein the MDV comprises one or more foreign genes which have been deleted.
30. The vaccine of Claim 25 wherein an immortalized Marek's disease herpesvirus cell line deposited as ATCC CRL-11985 Marek's disease strain Md11.
31. The vaccine of Claim 25 wherein the CEC fibroblasts is CHCC-OU2.




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5





Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 775 743 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
10.09.1997 Bulletin 1997/37

(51) Int. Cl.⁶: C12N 5/16, A61K 39/255

(43) Date of publication A2:
28.05.1997 Bulletin 1997/22

(21) Application number: 96115575.1

(22) Date of filing: 27.09.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE
Designated Extension States:
AL LT LV SI

(30) Priority: 27.10.1995 US 549045

(71) Applicant: MICHIGAN STATE UNIVERSITY
East Lansing, Michigan 48824 (US)

(72) Inventors:

- Colussens, Paul M.
DeWitt, Michigan 48820 (US)
- Abujoub, Amin
East Lansing, Michigan 48823 (US)

(74) Representative: Grünecker, Kinkeldey,
Stockmair & Schwanhäusser
Anwaltssozietät
Maximilianstrasse 58
80538 München (DE)

(54) Sustainable chick cell line infected with Marek's disease virus

(57) A sustainable cell line of a Marek's disease herpesvirus (MDV) infected chicken cell line derived from chick embryo cells which are chicken helper factor (Chf) negative and which have been treated with N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and then converted

with the MDV which is able to infect avians *in vivo*. The cell line is useful for vaccine production and for determining the characteristics of the MDV under various conditions.



FIG. 1A

EP 0 775 743 A3

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 11 5575

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P, X	VIROLOGY, vol. 214, 1995, pages 541-549, XP000652237 A. ABUJOUR AND P.M. COUSSENS : "Development of a sustainable cell line infected with Marek's disease virus" *see the whole article* ---	1-31	C12N5/16 A61K39/255
Y	ACTA MED. OKAYAMA, vol. 41, no. 3, 1987, pages 141-143, XP000654337 H. OGURA AND T. FUJIWARA: "Establishment and characterization of a virus-free chicken cell line" *see the whole article* ---	1-31	
Y	ADV. BIOTECHNOL. PROCESSES, vol. 14, 1990, pages 347-365, XP000603815 D. BEN-NATHAN AND S. LUSTIG: "Production of Marek's disease vaccine" *see the whole article* ---	1-31	TECHNICAL FIELDS SEARCHED (Int.Cl.4)
Y	ARCHIVES OF VIROLOGY, vol. 121, 1991, pages 125-139, XP000654273 I. DAVIDSON ET AL.: "Monospecific antibodies to MDV antigen B dimer (200kDa) and monomer (130 and 60 kDa) glycoproteins neutralize virus infectivity and detect the antigen B proteins in infected cell membranes" *see the whole article* ---	1-31	C12N A61K
-/-			
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 30 June 1997	Examiner Marie, A
CATEGORY OF CITED DOCUMENTS			
X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background Q: non-written disclosure P: intermediate document		T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document	

EPO FORM 1501 (01.81) (PWO/ST)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 11 5575

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	INTERNATIONAL JOURNAL OF CANCER, vol. 39, 1987, pages 514-520, XP000654932 K. IKUTA ET AL.: "establishment and characterization of a T-lymphoblastoid cell line MDCC-MTBI derived from chick lymphocytes infected in vitro with MDV serotype 1"	1	
Y	*see the whole article*	1-31	
Y	AVIAN DISEASES, vol. 28, no. 1, 1984, pages 160-168, XP000655036 K. NAZERIAN AND R.L. WITTER : "Immunization against Marek's disease transplantable cell lines" *see the whole article*	1-31	
Y	VIROLOGY, vol. 195, 1993, pages 638-648, XP000652334 D.R. MARSHALL ET AL.: "Selection of MDV recombinants expressing E. coli gpt gene" *see the whole article*	1-31	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 30 June 1997	Examiner Marie, A
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1501 (01/92) (PACI)

THIS PAGE BLANK (USPTO)